Sugi Predict

Sugi Predict / Compounds / SCHEMBL25317345

SCHEMBL25317345

SCHEMBL25317345

CC(C)(C)OC(=O)N1C(=O)CCc2cc(B3OC(C)(C)C(C)(C)O3)cnc21

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.45
▸ DGAT1 O75907 1/20 0.36
▸ PRMT5 O14744 1/20 0.35
▸ WDR77 Q9BQA1 1/20 0.35
▸ AAK1 Q2M2I8 3/20 0.33
▸ BACE1 P56817 1/20 0.33
▸ BACE2 Q9Y5Z0 1/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ PDGFRB P09619 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ CYP11B2 P19099 1/20 0.31
▸ HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21464134 0.83 USP30 (0.46) USP30DGAT1PRMT5WDR77AAK1
SCHEMBL16196126 0.81 USP30 (0.45) USP30DGAT1CYP11B2
SCHEMBL20424928 0.81 USP30 (0.40) USP30DGAT1PRMT5WDR77AAK1
SCHEMBL30507081 0.79 ESR2 (0.41) USP30NR1H2CYP11B2
SCHEMBL25317490 0.79 ESR2 (0.41) USP30NR1H2CYP11B2
SCHEMBL35211652 0.78 USP30 (0.44) USP30DGAT1PRMT5WDR77AAK1
SCHEMBL30507033 0.78 FNTA (0.38) DGAT1AAK1NR1H2CYP11B2
SCHEMBL25316077 0.78 FNTA (0.38) DGAT1AAK1NR1H2CYP11B2
SCHEMBL25313937 0.77 FFAR1 (0.46) USP30DGAT1PRMT5WDR77AAK1
SCHEMBL17948561 0.75 USP30 (0.49) USP30DGAT1PRMT5WDR77NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR USP30 2796/4885DGAT1 2874/4885PRMT5 2999/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 USP30 2692/4885DGAT1 2985/4885PRMT5 2897/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR USP30 2796/4885DGAT1 2874/4885PRMT5 2999/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 USP30 2692/4885DGAT1 2985/4885PRMT5 2897/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 USP30 2692/4885DGAT1 2985/4885PRMT5 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.